FDA approves AstraZeneca’s asthma drug: 3 things to know

AstraZeneca on Wednesday earned Food and Drug Administration approval for its asthma drug Fasenra.

Advertisement

Here are three things to know.

1. Fasenra is respiratory biologic used as a maintenance treatment for patients 12 years and older with severe asthma.

 

2. The drug is administered as a fixed-dose subcutaneous injection once a month for the first three doses, and then once every two months.

 

3. The first year of treatment will cost $38,000, with following annual treatment costs ranging from $28,000 to $33,000, depending on how many doses the patient receives, according to Reuters.

More articles on supply chain:

Hospitals face critical saline bag shortage: 6 things to know
Amazon: We will use pharmacy licenses in Indiana, Tennessee to sell medical devices, not medication
Prime Healthcare taps HealthTrust for GPO services

Advertisement

Next Up in Supply Chain

Advertisement

Comments are closed.